EMEA (Europe, Middle East and Africa) Orphan Drugs Market Report 2017

November 2017 | 119 pages | ID: EB6CF7F2916EN
QYResearch

Abstracts

In this report, the EMEA Orphan Drugs market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report split EMEA into Europe, the Middle East and Africa, With sales (K Units), revenue (Million USD), market share and growth rate of Orphan Drugs for these regions, from 2012 to 2022 (forecast)

• Europe: Germany, France, UK, Russia, Italy and Benelux;
• Middle East: Saudi Arabia, Israel, UAE and Iran;
• Africa: South Africa, Nigeria, Egypt and Algeria.

EMEA Orphan Drugs market competition by top manufacturers/players, with Orphan Drugs sales volume (K Units), price (USD/Unit), revenue (Million USD) and market share for each manufacturer/player; the top players including

• Novartis AG
• Bristol-Myers Squibb Company
• Celgene Corporation
• F. Hoffmann-La Roche Ltd.
• Pfizer, Inc.
• Sanofi S.A.
• Alexion Pharmaceuticals, Inc.
• Eli Lilly and Company
• Novo Nordisk A/S
• AstraZeneca
• Eisai Co., Ltd.
• Daiichi Sankyo Company Limited
• Bayer AG
• GlaxoSmithKline
• Merck & Co., Inc.
• Johnson & Johnson
• Biogen, Inc.
• Shire
• Amgen, Inc.

On the basis of product, this report displays the sales volume (K Units), revenue (Million USD), product price (USD/Unit), market share and growth rate of each type, primarily split into

• Oncology
• Gastrointestinal
• Pulmonary
• Neurology
• Hematology
• Cardio-vascular
• Metabolic disorders
• Endocrinology
• Infectious diseases
• Others

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume (K Units), market share and growth rate of Orphan Drugs for each application, including

• Hospital Pharmacies
• Speciality Pharmacies
• Retail pharmacies
• Others

If you have any special requirements, please let us know and we will offer you the report as you want.

Contents

EMEA (Europe, Middle East and Africa) Orphan Drugs Market Report 2017

1 ORPHAN DRUGS OVERVIEW

1.1 Product Overview and Scope of Orphan Drugs
1.2 Classification of Orphan Drugs
  1.2.1 EMEA Orphan Drugs Market Size (Sales) Comparison by Type (2012-2022)
  1.2.2 EMEA Orphan Drugs Market Size (Sales) Market Share by Type (Product Category) in 2016
  1.2.3 Oncology
  1.2.4 Gastrointestinal
  1.2.5 Pulmonary
  1.2.6 Neurology
  1.2.7 Hematology
  1.2.8 Cardio-vascular
  1.2.9 Metabolic disorders
  1.2.10 Endocrinology
  1.2.11 Infectious diseases
  1.2.12 Others
1.3 EMEA Orphan Drugs Market by Application/End Users
  1.3.1 EMEA Orphan Drugs Sales (Volume) and Market Share Comparison by Application (2012-2022
  1.3.2 Hospital Pharmacies
  1.3.3 Speciality Pharmacies
  1.3.4 Retail pharmacies
  1.3.5 Others
1.4 EMEA Orphan Drugs Market by Region
  1.4.1 EMEA Orphan Drugs Market Size (Value) Comparison by Region (2012-2022)
  1.4.2 Europe Status and Prospect (2012-2022)
  1.4.3 Middle East Status and Prospect (2012-2022)
  1.4.4 Africa Status and Prospect (2012-2022)
1.5 EMEA Market Size (Value and Volume) of Orphan Drugs (2012-2022)
  1.5.1 EMEA Orphan Drugs Sales and Growth Rate (2012-2022)
  1.5.2 EMEA Orphan Drugs Revenue and Growth Rate (2012-2022)

2 EMEA ORPHAN DRUGS COMPETITION BY MANUFACTURERS/PLAYERS/SUPPLIERS, REGION, TYPE AND APPLICATION

2.1 EMEA Orphan Drugs Market Competition by Players/Manufacturers
  2.1.1 EMEA Orphan Drugs Sales Volume and Market Share of Major Players (2012-2017)
  2.1.2 EMEA Orphan Drugs Revenue and Share by Players (2012-2017)
  2.1.3 EMEA Orphan Drugs Sale Price by Players (2012-2017)
2.2 EMEA Orphan Drugs (Volume and Value) by Type/Product Category
  2.2.1 EMEA Orphan Drugs Sales and Market Share by Type (2012-2017)
  2.2.2 EMEA Orphan Drugs Revenue and Market Share by Type (2012-2017)
  2.2.3 EMEA Orphan Drugs Sale Price by Type (2012-2017)
2.3 EMEA Orphan Drugs (Volume) by Application
2.4 EMEA Orphan Drugs (Volume and Value) by Region
  2.4.1 EMEA Orphan Drugs Sales and Market Share by Region (2012-2017)
  2.4.2 EMEA Orphan Drugs Revenue and Market Share by Region (2012-2017)
  2.4.3 EMEA Orphan Drugs Sales Price by Region (2012-2017)

3 EUROPE ORPHAN DRUGS (VOLUME, VALUE AND SALES PRICE), BY PLAYERS, COUNTRIES, TYPE AND APPLICATION

3.1 Europe Orphan Drugs Sales and Value (2012-2017)
  3.1.1 Europe Orphan Drugs Sales Volume and Growth Rate (2012-2017)
  3.1.2 Europe Orphan Drugs Revenue and Growth Rate (2012-2017)
3.2 Europe Orphan Drugs Sales and Market Share by Type
3.3 Europe Orphan Drugs Sales and Market Share by Application
3.4 Europe Orphan Drugs Sales Volume and Value (Revenue) by Countries
  3.4.1 Europe Orphan Drugs Sales Volume by Countries (2012-2017)
  3.4.2 Europe Orphan Drugs Revenue by Countries (2012-2017)
  3.4.3 Germany Orphan Drugs Sales and Growth Rate (2012-2017)
  3.4.4 France Orphan Drugs Sales and Growth Rate (2012-2017)
  3.4.5 UK Orphan Drugs Sales and Growth Rate (2012-2017)
  3.4.6 Russia Orphan Drugs Sales and Growth Rate (2012-2017)
  3.4.7 Italy Orphan Drugs Sales and Growth Rate (2012-2017)
  3.4.8 Benelux Orphan Drugs Sales and Growth Rate (2012-2017)

4 MIDDLE EAST ORPHAN DRUGS (VOLUME, VALUE AND SALES PRICE), BY REGION, TYPE AND APPLICATION

4.1 Middle East Orphan Drugs Sales and Value (2012-2017)
  4.1.1 Middle East Orphan Drugs Sales Volume and Growth Rate (2012-2017)
  4.1.2 Middle East Orphan Drugs Revenue and Growth Rate (2012-2017)
4.2 Middle East Orphan Drugs Sales and Market Share by Type
4.3 Middle East Orphan Drugs Sales and Market Share by Application
4.4 Middle East Orphan Drugs Sales Volume and Value (Revenue) by Countries
  4.4.1 Middle East Orphan Drugs Sales Volume by Countries (2012-2017)
  4.4.2 Middle East Orphan Drugs Revenue by Countries (2012-2017)
  4.4.3 Saudi Arabia Orphan Drugs Sales and Growth Rate (2012-2017)
  4.4.4 Israel Orphan Drugs Sales and Growth Rate (2012-2017)
  4.4.5 UAE Orphan Drugs Sales and Growth Rate (2012-2017)
  4.4.6 Iran Orphan Drugs Sales and Growth Rate (2012-2017)

5 AFRICA ORPHAN DRUGS (VOLUME, VALUE AND SALES PRICE) BY PLAYERS, COUNTRIES, TYPE AND APPLICATION

5.1 Africa Orphan Drugs Sales and Value (2012-2017)
  5.1.1 Africa Orphan Drugs Sales Volume and Growth Rate (2012-2017)
  5.1.2 Africa Orphan Drugs Revenue and Growth Rate (2012-2017)
5.2 Africa Orphan Drugs Sales and Market Share by Type
5.3 Africa Orphan Drugs Sales and Market Share by Application
5.4 Africa Orphan Drugs Sales Volume and Value (Revenue) by Countries
  5.4.1 Africa Orphan Drugs Sales Volume by Countries (2012-2017)
  5.4.2 Africa Orphan Drugs Revenue by Countries (2012-2017)
  5.4.3 South Africa Orphan Drugs Sales and Growth Rate (2012-2017)
  5.4.4 Nigeria Orphan Drugs Sales and Growth Rate (2012-2017)
  5.4.5 Egypt Orphan Drugs Sales and Growth Rate (2012-2017)
  5.4.6 Algeria Orphan Drugs Sales and Growth Rate (2012-2017)

6 EMEA ORPHAN DRUGS MANUFACTURERS/PLAYERS PROFILES AND SALES DATA

6.1 Novartis AG
  6.1.1 Company Basic Information, Manufacturing Base and Competitors
  6.1.2 Orphan Drugs Product Type, Application and Specification
    6.1.2.1 Product A
    6.1.2.2 Product B
  6.1.3 Novartis AG Orphan Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.1.4 Main Business/Business Overview
6.2 Bristol-Myers Squibb Company
  6.2.1 Company Basic Information, Manufacturing Base and Competitors
  6.2.2 Orphan Drugs Product Type, Application and Specification
    6.2.2.1 Product A
    6.2.2.2 Product B
  6.2.3 Bristol-Myers Squibb Company Orphan Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.2.4 Main Business/Business Overview
6.3 Celgene Corporation
  6.3.1 Company Basic Information, Manufacturing Base and Competitors
  6.3.2 Orphan Drugs Product Type, Application and Specification
    6.3.2.1 Product A
    6.3.2.2 Product B
  6.3.3 Celgene Corporation Orphan Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.3.4 Main Business/Business Overview
6.4 F. Hoffmann-La Roche Ltd.
  6.4.1 Company Basic Information, Manufacturing Base and Competitors
  6.4.2 Orphan Drugs Product Type, Application and Specification
    6.4.2.1 Product A
    6.4.2.2 Product B
  6.4.3 F. Hoffmann-La Roche Ltd. Orphan Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.4.4 Main Business/Business Overview
6.5 Pfizer, Inc.
  6.5.1 Company Basic Information, Manufacturing Base and Competitors
  6.5.2 Orphan Drugs Product Type, Application and Specification
    6.5.2.1 Product A
    6.5.2.2 Product B
  6.5.3 Pfizer, Inc. Orphan Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.5.4 Main Business/Business Overview
6.6 Sanofi S.A.
  6.6.1 Company Basic Information, Manufacturing Base and Competitors
  6.6.2 Orphan Drugs Product Type, Application and Specification
    6.6.2.1 Product A
    6.6.2.2 Product B
  6.6.3 Sanofi S.A. Orphan Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.6.4 Main Business/Business Overview
6.7 Alexion Pharmaceuticals, Inc.
  6.7.1 Company Basic Information, Manufacturing Base and Competitors
  6.7.2 Orphan Drugs Product Type, Application and Specification
    6.7.2.1 Product A
    6.7.2.2 Product B
  6.7.3 Alexion Pharmaceuticals, Inc. Orphan Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.7.4 Main Business/Business Overview
6.8 Eli Lilly and Company
  6.8.1 Company Basic Information, Manufacturing Base and Competitors
  6.8.2 Orphan Drugs Product Type, Application and Specification
    6.8.2.1 Product A
    6.8.2.2 Product B
  6.8.3 Eli Lilly and Company Orphan Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.8.4 Main Business/Business Overview
6.9 Novo Nordisk A/S
  6.9.1 Company Basic Information, Manufacturing Base and Competitors
  6.9.2 Orphan Drugs Product Type, Application and Specification
    6.9.2.1 Product A
    6.9.2.2 Product B
  6.9.3 Novo Nordisk A/S Orphan Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.9.4 Main Business/Business Overview
6.10 AstraZeneca
  6.10.1 Company Basic Information, Manufacturing Base and Competitors
  6.10.2 Orphan Drugs Product Type, Application and Specification
    6.10.2.1 Product A
    6.10.2.2 Product B
  6.10.3 AstraZeneca Orphan Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.10.4 Main Business/Business Overview
6.11 Eisai Co., Ltd.
6.12 Daiichi Sankyo Company Limited
6.13 Bayer AG
6.14 GlaxoSmithKline
6.15 Merck & Co., Inc.
6.16 Johnson & Johnson
6.17 Biogen, Inc.
6.18 Shire
6.19 Amgen, Inc.

7 ORPHAN DRUGS MANUFACTURING COST ANALYSIS

7.1 Orphan Drugs Key Raw Materials Analysis
  7.1.1 Key Raw Materials
  7.1.2 Price Trend of Key Raw Materials
  7.1.3 Key Suppliers of Raw Materials
  7.1.4 Market Concentration Rate of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
  7.2.1 Raw Materials
  7.2.2 Labor Cost
  7.2.3 Manufacturing Expenses
7.3 Manufacturing Process Analysis of Orphan Drugs

8 INDUSTRIAL CHAIN, SOURCING STRATEGY AND DOWNSTREAM BUYERS

8.1 Orphan Drugs Industrial Chain Analysis
8.2 Upstream Raw Materials Sourcing
8.3 Raw Materials Sources of Orphan Drugs Major Manufacturers in 2016
8.4 Downstream Buyers

9 MARKETING STRATEGY ANALYSIS, DISTRIBUTORS/TRADERS

9.1 Marketing Channel
  9.1.1 Direct Marketing
  9.1.2 Indirect Marketing
  9.1.3 Marketing Channel Development Trend
9.2 Market Positioning
  9.2.1 Pricing Strategy
  9.2.2 Brand Strategy
  9.2.3 Target Client
9.3 Distributors/Traders List

10 MARKET EFFECT FACTORS ANALYSIS

10.1 Technology Progress/Risk
  10.1.1 Substitutes Threat
  10.1.2 Technology Progress in Related Industry
10.2 Consumer Needs/Customer Preference Change
10.3 Economic/Political Environmental Change

11 EMEA ORPHAN DRUGS MARKET FORECAST (2017-2022)

11.1 EMEA Orphan Drugs Sales, Revenue and Price Forecast (2017-2022)
  11.1.1 EMEA Orphan Drugs Sales and Growth Rate Forecast (2017-2022)
  11.1.2 EMEA Orphan Drugs Revenue and Growth Rate Forecast (2017-2022)
  11.1.3 EMEA Orphan Drugs Price and Trend Forecast (2017-2022)
11.2 EMEA Orphan Drugs Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
11.3 Europe Orphan Drugs Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
11.4 Middle Eastt Orphan Drugs Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
11.5 Africa Orphan Drugs Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
11.6 EMEA Orphan Drugs Sales Forecast by Type (2017-2022)
11.7 EMEA Orphan Drugs Sales Forecast by Application (2017-2022)

12 RESEARCH FINDINGS AND CONCLUSION

13 APPENDIX

13.1 Methodology/Research Approach
  13.1.1 Research Programs/Design
  13.1.2 Market Size Estimation
  13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
  13.2.1 Secondary Sources
  13.2.2 Primary Sources
13.3 Disclaimer


The report requires updating with new data and is sent in 2-3 business days after order is placed.

List Of Tables

LIST OF TABLES AND FIGURES

Figure Product Picture of Orphan Drugs
Figure EMEA Orphan Drugs Sales Volume (K Units) by Type (2012-2022)
Figure EMEA Orphan Drugs Sales Volume Market Share by Type (Product Category) in 2016
Figure Oncology Product Picture
Figure Gastrointestinal Product Picture
Figure Pulmonary Product Picture
Figure Neurology Product Picture
Figure Hematology Product Picture
Figure Cardio-vascular Product Picture
Figure Metabolic disorders Product Picture
Figure Endocrinology Product Picture
Figure Infectious diseases Product Picture
Figure Others Product Picture
Figure EMEA Orphan Drugs Sales Volume (K Units) by Application (2012-2022)
Figure EMEA Sales Market Share of Orphan Drugs by Application in 2016
Figure Hospital Pharmacies Examples
Table Key Downstream Customer in Hospital Pharmacies
Figure Speciality Pharmacies Examples
Table Key Downstream Customer in Speciality Pharmacies
Figure Retail pharmacies Examples
Table Key Downstream Customer in Retail pharmacies
Figure Others Examples
Table Key Downstream Customer in Others
Figure EMEA Orphan Drugs Market Size (Million USD) by Region (2012-2022)
Figure Europe Orphan Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure Europe Orphan Drugs Revenue (Million USD) Status and Forecast by Countries
Figure Middle East Orphan Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure Middle East Orphan Drugs Revenue (Million USD) Status and Forecast by Countries
Figure Africa Orphan Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure Africa Orphan Drugs Revenue (Million USD) Status and Forecast by Countries
Figure EMEA Orphan Drugs Sales Volume and Growth Rate (2012-2022)
Figure EMEA Orphan Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure EMEA Orphan Drugs Market Major Players Product Sales Volume (K Units) (2012-2017)
Table EMEA Orphan Drugs Sales Volume (K Units) of Major Players (2012-2017)
Table EMEA Orphan Drugs Sales Share by Players (2012-2017)
Figure 2016 Orphan Drugs Sales Share by Players
Figure 2017 Orphan Drugs Sales Share by Players
Figure EMEA Orphan Drugs Market Major Players Product Revenue (Million USD) (2012-2017)
Table EMEA Orphan Drugs Revenue (Million USD) by Players (2012-2017)
Table EMEA Orphan Drugs Revenue Share by Players (2012-2017)
Table 2016 EMEA Orphan Drugs Revenue Share by Players
Table 2017 EMEA Orphan Drugs Revenue Share by Players
Table EMEA Orphan Drugs Sale Price (USD/Unit) by Players (2012-2017)
Table EMEA Orphan Drugs Sales (K Units) and Market Share by Type (2012-2017)
Table EMEA Orphan Drugs Sales Share by Type (2012-2017)
Figure Sales Market Share of Orphan Drugs by Type (2012-2017)
Figure EMEA Orphan Drugs Sales Market Share by Type (2012-2017)
Table EMEA Orphan Drugs Revenue (Million USD) and Market Share by Type (2012-2017)
Table EMEA Orphan Drugs Revenue Share by Type (2012-2017)
Figure Revenue Market Share of Orphan Drugs by Type in 2016
Table EMEA Orphan Drugs Sale Price (USD/Unit) by Type (2012-2017)
Table EMEA Orphan Drugs Sales (K Units) and Market Share by Application (2012-2017)
Table EMEA Orphan Drugs Sales Share by Application (2012-2017)
Figure Sales Market Share of Orphan Drugs by Application (2012-2017)
Figure EMEA Orphan Drugs Sales Market Share by Application in 2016
Table EMEA Orphan Drugs Sales (K Units) and Market Share by Region (2012-2017)
Table EMEA Orphan Drugs Sales Share by Region (2012-2017)
Figure Sales Market Share of Orphan Drugs by Region (2012-2017)
Figure EMEA Orphan Drugs Sales Market Share in 2016
Table EMEA Orphan Drugs Revenue (Million USD) and Market Share by Region (2012-2017)
Table EMEA Orphan Drugs Revenue Share by Region (2012-2017)
Figure Revenue Market Share of Orphan Drugs by Region (2012-2017)
Figure EMEA Orphan Drugs Revenue Market Share Regions in 2016
Table EMEA Orphan Drugs Sales Price (USD/Unit) by Region (2012-2017)
Figure Europe Orphan Drugs Sales (K Units) and Growth Rate (2012-2017)
Figure Europe Orphan Drugs Revenue and Growth Rate (2012-2017)
Table Europe Orphan Drugs Sales (K Units) by Type (2012-2017)
Table Europe Orphan Drugs Market Share by Type (2012-2017)
Figure Europe Orphan Drugs Market Share by Type in 2016
Table Europe Orphan Drugs Sales (K Units) by Application (2012-2017)
Table Europe Orphan Drugs Market Share by Application (2012-2017)
Figure Europe Orphan Drugs Market Share by Application in 2016
Table Europe Orphan Drugs Sales (K Units) by Countries (2012-2017)
Table Europe Orphan Drugs Sales Market Share by Countries (2012-2017)
Figure Europe Orphan Drugs Sales Market Share by Countries (2012-2017)
Figure Europe Orphan Drugs Sales Market Share by Countries in 2016
Table Europe Orphan Drugs Revenue (Million USD) by Countries (2012-2017)
Table Europe Orphan Drugs Revenue Market Share by Countries (2012-2017)
Figure Europe Orphan Drugs Revenue Market Share by Countries (2012-2017)
Figure Europe Orphan Drugs Revenue Market Share by Countries in 2016
Figure Germany Orphan Drugs Sales (K Units) and Growth Rate (2012-2017)
Figure France Orphan Drugs Sales (K Units) and Growth Rate (2012-2017)
Figure UK Orphan Drugs Sales (K Units) and Growth Rate (2012-2017)
Figure Russia Orphan Drugs Sales (K Units) and Growth Rate (2012-2017)
Figure Italy Orphan Drugs Sales (K Units) and Growth Rate (2012-2017)
Figure Benelux Orphan Drugs Sales (K Units) and Growth Rate (2012-2017)
Figure Middle East Orphan Drugs Sales (K Units) and Growth Rate (2012-2017)
Figure Middle East Orphan Drugs Revenue (Million USD) and Growth Rate (2012-2017)
Table Middle East Orphan Drugs Sales (K Units) by Type (2012-2017)
Table Middle East Orphan Drugs Market Share by Type (2012-2017)
Figure Middle East Orphan Drugs Market Share by Type (2012-2017)
Table Middle East Orphan Drugs Sales (K Units) by Applications (2012-2017)
Table Middle East Orphan Drugs Market Share by Applications (2012-2017)
Figure Middle East Orphan Drugs Sales Market Share by Application in 2016
Table Middle East Orphan Drugs Sales Volume (K Units) by Countries (2012-2017)
Table Middle East Orphan Drugs Sales Volume Market Share by Countries (2012-2017)
Figure Middle East Orphan Drugs Sales Volume Market Share by Countries in 2016
Table Middle East Orphan Drugs Revenue (Million USD) by Countries (2012-2017)
Table Middle East Orphan Drugs Revenue Market Share by Countries (2012-2017)
Figure Middle East Orphan Drugs Revenue Market Share by Countries (2012-2017)
Figure Middle East Orphan Drugs Revenue Market Share by Countries in 2016
Figure Saudi Arabia Orphan Drugs Sales (K Units) and Growth Rate (2012-2017)
Figure Israel Orphan Drugs Sales (K Units) and Growth Rate (2012-2017)
Figure UAE Orphan Drugs Sales (K Units) and Growth Rate (2012-2017)
Figure Iran Orphan Drugs Sales (K Units) and Growth Rate (2012-2017)
Figure Africa Orphan Drugs Sales (K Units) and Growth Rate (2012-2017)
Figure Africa Orphan Drugs Revenue (Million USD) and Growth Rate (2012-2017)
Table Africa Orphan Drugs Sales (K Units) by Type (2012-2017)
Table Africa Orphan Drugs Sales Market Share by Type (2012-2017)
Figure Africa Orphan Drugs Sales Market Share by Type (2012-2017)
Figure Africa Orphan Drugs Sales Market Share by Type in 2016
Table Africa Orphan Drugs Sales (K Units) by Application (2012-2017)
Table Africa Orphan Drugs Sales Market Share by Application (2012-2017)
Figure Africa Orphan Drugs Sales Market Share by Application (2012-2017)
Table Africa Orphan Drugs Sales Volume (K Units) by Countries (2012-2017)
Table Africa Orphan Drugs Sales Market Share by Countries (2012-2017)
Figure Africa Orphan Drugs Sales Market Share by Countries (2012-2017)
Figure Africa Orphan Drugs Sales Market Share by Countries in 2016
Table Africa Orphan Drugs Revenue (Million USD) by Countries (2012-2017)
Table Africa Orphan Drugs Revenue Market Share by Countries (2012-2017)
Figure Africa Orphan Drugs Revenue Market Share by Countries (2012-2017)
Figure Africa Orphan Drugs Revenue Market Share by Countries in 2016
Figure South Africa Orphan Drugs Sales (K Units) and Growth Rate (2012-2017)
Figure Nigeria Orphan Drugs Sales (K Units) and Growth Rate (2012-2017)
Figure Egypt Orphan Drugs Sales (K Units) and Growth Rate (2012-2017)
Figure Algeria Orphan Drugs Sales (K Units) and Growth Rate (2012-2017)
Table Novartis AG Orphan Drugs Basic Information List
Table Novartis AG Orphan Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Novartis AG Orphan Drugs Sales (K Units) and Growth Rate (2012-2017)
Figure Novartis AG Orphan Drugs Sales Market Share in EMEA (2012-2017)
Figure Novartis AG Orphan Drugs Revenue Market Share in EMEA (2012-2017)
Table Bristol-Myers Squibb Company Orphan Drugs Basic Information List
Table Bristol-Myers Squibb Company Orphan Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Bristol-Myers Squibb Company Orphan Drugs Sales (K Units) and Growth Rate (2012-2017)
Figure Bristol-Myers Squibb Company Orphan Drugs Sales Market Share in EMEA (2012-2017)
Figure Bristol-Myers Squibb Company Orphan Drugs Revenue Market Share in EMEA (2012-2017)
Table Celgene Corporation Orphan Drugs Basic Information List
Table Celgene Corporation Orphan Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Celgene Corporation Orphan Drugs Sales (K Units) and Growth Rate (2012-2017)
Figure Celgene Corporation Orphan Drugs Sales Market Share in EMEA (2012-2017)
Figure Celgene Corporation Orphan Drugs Revenue Market Share in EMEA (2012-2017)
Table F. Hoffmann-La Roche Ltd. Orphan Drugs Basic Information List
Table F. Hoffmann-La Roche Ltd. Orphan Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure F. Hoffmann-La Roche Ltd. Orphan Drugs Sales (K Units) and Growth Rate (2012-2017)
Figure F. Hoffmann-La Roche Ltd. Orphan Drugs Sales Market Share in EMEA (2012-2017)
Figure F. Hoffmann-La Roche Ltd. Orphan Drugs Revenue Market Share in EMEA (2012-2017)
Table Pfizer, Inc. Orphan Drugs Basic Information List
Table Pfizer, Inc. Orphan Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Pfizer, Inc. Orphan Drugs Sales (K Units) and Growth Rate (2012-2017)
Figure Pfizer, Inc. Orphan Drugs Sales Market Share in EMEA (2012-2017)
Figure Pfizer, Inc. Orphan Drugs Revenue Market Share in EMEA (2012-2017)
Table Sanofi S.A. Orphan Drugs Basic Information List
Table Sanofi S.A. Orphan Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Sanofi S.A. Orphan Drugs Sales (K Units) and Growth Rate (2012-2017)
Figure Sanofi S.A. Orphan Drugs Sales Market Share in EMEA (2012-2017)
Figure Sanofi S.A. Orphan Drugs Revenue Market Share in EMEA (2012-2017)
Table Alexion Pharmaceuticals, Inc. Orphan Drugs Basic Information List
Table Alexion Pharmaceuticals, Inc. Orphan Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Alexion Pharmaceuticals, Inc. Orphan Drugs Sales (K Units) and Growth Rate (2012-2017)
Figure Alexion Pharmaceuticals, Inc. Orphan Drugs Sales Market Share in EMEA (2012-2017)
Figure Alexion Pharmaceuticals, Inc. Orphan Drugs Revenue Market Share in EMEA (2012-2017)
Table Eli Lilly and Company Orphan Drugs Basic Information List
Table Eli Lilly and Company Orphan Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Eli Lilly and Company Orphan Drugs Sales (K Units) and Growth Rate (2012-2017)
Figure Eli Lilly and Company Orphan Drugs Sales Market Share in EMEA (2012-2017)
Figure Eli Lilly and Company Orphan Drugs Revenue Market Share in EMEA (2012-2017)
Table Novo Nordisk A/S Orphan Drugs Basic Information List
Table Novo Nordisk A/S Orphan Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Novo Nordisk A/S Orphan Drugs Sales (K Units) and Growth Rate (2012-2017)
Figure Novo Nordisk A/S Orphan Drugs Sales Market Share in EMEA (2012-2017)
Figure Novo Nordisk A/S Orphan Drugs Revenue Market Share in EMEA (2012-2017)
Table AstraZeneca Orphan Drugs Basic Information List
Table AstraZeneca Orphan Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure AstraZeneca Orphan Drugs Sales (K Units) and Growth Rate (2012-2017)
Figure AstraZeneca Orphan Drugs Sales Market Share in EMEA (2012-2017)
Figure AstraZeneca Orphan Drugs Revenue Market Share in EMEA (2012-2017)
Table Eisai Co., Ltd. Orphan Drugs Basic Information List
Table Daiichi Sankyo Company Limited Orphan Drugs Basic Information List
Table Bayer AG Orphan Drugs Basic Information List
Table GlaxoSmithKline Orphan Drugs Basic Information List
Table Merck & Co., Inc. Orphan Drugs Basic Information List
Table Johnson & Johnson Orphan Drugs Basic Information List
Table Biogen, Inc. Orphan Drugs Basic Information List
Table Shire Orphan Drugs Basic Information List
Table Amgen, Inc. Orphan Drugs Basic Information List
Table Production Base and Market Concentration Rate of Raw Material
Figure Price Trend of Key Raw Materials
Table Key Suppliers of Raw Materials
Figure Manufacturing Cost Structure of Orphan Drugs
Figure Manufacturing Process Analysis of Orphan Drugs
Figure Orphan Drugs Industrial Chain Analysis
Table Raw Materials Sources of Orphan Drugs Major Manufacturers in 2016
Table Major Buyers of Orphan Drugs
Table Distributors/Traders List
Figure EMEA Orphan Drugs Sales (K Units) and Growth Rate Forecast (2017-2022)
Figure EMEA Orphan Drugs Revenue and Growth Rate Forecast (2017-2022)
Figure EMEA Orphan Drugs Price (USD/Unit) and Trend Forecast (2017-2022)
Table EMEA Orphan Drugs Sales (K Units) Forecast by Region (2017-2022)
Figure EMEA Orphan Drugs Sales Market Share Forecast by Region (2017-2022)
Table EMEA Orphan Drugs Revenue (Million USD) Forecast by Region (2017-2022)
Figure EMEA Orphan Drugs Revenue Market Share Forecast by Region (2017-2022)
Table Europe Orphan Drugs Sales (K Units) Forecast by Countries (2017-2022)
Figure Europe Orphan Drugs Sales Market Share Forecast by Countries (2017-2022)
Table Europe Orphan Drugs Revenue (Million USD) Forecast by Countries (2017-2022)
Figure Europe Orphan Drugs Revenue Market Share Forecast by Countries (2017-2022)
Table Middle East Orphan Drugs Sales (K Units) Forecast by Countries (2017-2022)
Figure Middle East Orphan Drugs Sales Market Share Forecast by Countries (2017-2022)
Table Middle East Orphan Drugs Revenue (Million USD) Forecast by Countries (2017-2022)
Figure Middle East Orphan Drugs Revenue Market Share Forecast by Countries (2017-2022)
Table Africa Orphan Drugs Sales (K Units) Forecast by Countries (2017-2022)
Figure Africa Orphan Drugs Sales Market Share Forecast by Countries (2017-2022)
Table Africa Orphan Drugs Revenue (Million USD) Forecast by Countries (2017-2022)
Figure Africa Orphan Drugs Revenue Market Share Forecast by Countries (2017-2022)
Table EMEA Orphan Drugs Sales (K Units) Forecast by Type (2017-2022)
Figure EMEA Orphan Drugs Sales Market Share Forecast by Type (2017-2022)
Table EMEA Orphan Drugs Sales (K Units) Forecast by Application (2017-2022)
Figure EMEA Orphan Drugs Sales Market Share Forecast by Application (2017-2022)
Table Research Programs/Design for This Report
Figure Bottom-up and Top-down Approaches for This Report
Figure Data Triangulation
Table Key Data Information from Secondary Sources
Table Key Data Information from Primary Sources